BIIB vs GSK: Biogen and GlaxoSmithKline PLC ADR compared
The short version
From the latest prices and each company's SEC filings. Who's ahead on each measure, not which to buy.
- GlaxoSmithKline PLC ADR is the larger company, worth $93.4B, about 3.1 times Biogen.
- GlaxoSmithKline PLC ADR grew revenue faster over the last year (+4.1% vs +1.9%).
- GlaxoSmithKline PLC ADR keeps more of each dollar of revenue as operating profit (24.3% vs 16.3%).
- On earnings, GlaxoSmithKline PLC ADR is the cheaper stock (12.3x vs 22.2x).
Side by side
The stronger figure is shaded where higher (or, for valuation multiples, lower) reads as better. How the implied growth works.
| Measure | BIIB | GSK |
|---|---|---|
| Market cap | $30.4B | $93.4B |
| Share price | $218.43 | $46.50 |
| Revenue (last fiscal year) | $9.9B | $32.7B |
| Free cash flow (last fiscal year) | $2.1B | $4.8B |
| Revenue growth, last year | +1.9% | +4.1% |
| Revenue growth per year, last 5 fiscal years | -2.6% | +7.2% |
| Operating margin | 16.3% | 24.3% |
| Net margin | 13.8% | 17.5% |
| Return on equity | 7.4% | 34.9% |
| P/E (trailing) | 22.2x | 12.3x |
| Price / free cash flow | 14.8x | 16.0x |
| EV / EBITDA | 12.1x | 9.29x |
| FCF growth the price implies | 1.1% | — |
| Dividend yield | — | 3.9% |
| Debt / equity | 0.58x | 2.76x |
| Fundamental grade | B | B |
| Superinvestors holding it | 5 | 9 |
| Insider purchases, last 12 months | 5 | 1 |
Results from SEC filings
Revenue and free cash flow by fiscal year, from each company's 10-K filings.
Biogen
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $11.0B | $3.4B | 25.9% |
| 2022 | $10.2B | $1.1B | 35.3% |
| 2023 | $9.8B | $1.3B | 13.2% |
| 2024 | $9.7B | $2.7B | 19.7% |
| 2025 | $9.9B | $2.1B | 15.7% |
GlaxoSmithKline PLC ADR
| Year | Revenue | Free cash flow | Op. margin |
|---|---|---|---|
| 2021 | $24.7B | $5.3B | 17.6% |
| 2022 | $29.3B | $5.1B | 21.9% |
| 2023 | $30.3B | $4.4B | 22.2% |
| 2024 | $31.4B | $3.6B | 12.8% |
| 2025 | $32.7B | $4.8B | 24.3% |
Where the revenue comes from
Biogen · by products, 2025
Product revenue, net$7.1B72%
Revenue from anti-CD20 therapeutic programs$1.9B19%
Contract manufacturing, royalty and other revenue$733M7%
Alzheimer's collaboration revenue$178M2%
GlaxoSmithKline PLC ADR · by products, 2023
Respiratory$6.8B23%
HIV$6.4B21%
Shingles$3.4B11%
Other General Medicines$3.4B11%
Established Vaccines$3.3B11%
Respiratory/Immunology and Other$3.0B10%
Compare them in fullFifteen years of statements, quarterly results, DCF and IRR models, and any number of peers side by side.
Open BIIB in InvestinglyQuestions
Which is bigger, Biogen or GlaxoSmithKline PLC ADR?
GlaxoSmithKline PLC ADR (GSK), at $93.4B against $30.4B.
Is BIIB or GSK cheaper?
By trailing P/E, GlaxoSmithKline PLC ADR (12.3x) is cheaper than Biogen (22.2x). A lower multiple can also mean the market expects less growth.
Which grows faster, BIIB or GSK?
GlaxoSmithKline PLC ADR: revenue grew +4.1% over the last year, against +1.9%.
More comparisons
Prices and ratios as of the last daily update; statements from SEC filings. Information only, not investment advice.